Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Expands Immuno-Oncology Efforts, Calls MK-3475 A Pipeline In Itself

Executive Summary

Rolling BLA for MK-3475 accepted for priority review with a PDUFA date of Oct. 28. Merck is undertaking or plans trials testing the anti-PD-1 candidate in 10 types of cancer and is seeking response signals in another 20 tumor types.

You may also be interested in...



AbbVie Banks On “Pipeline In A Molecule” Strategy For Imbruvica

AbbVie CEO Richard Gonzalez defended the roughly $21 billion purchase price it offered to pay for Pharmacyclics, citing bullish long-term sales projections for Imbruvica driven by indication expansion.

Merck Drives Into Immunotherapy “Wild West” With New Trials

Company moves fast to test pembrolizumab in head and neck cancer, among other new frontier tumor types. The firm has reorganized its oncology business to prepare for launch in melanoma, which will be a critical test of the company’s ambitions to become a cancer powerhouse.

Focus On The Core: Merck Claims R&D Restructuring Poised To Produce Results

At an R&D day presentation in Boston, Merck executives claimed R&D restructuring is beginning to bear fruit, presenting the pharma with a host of near-term launch possibilities. Outside of cancer immunotherapy, Merck has obtained or anticipates approvals in cardiovascular health, insomnia, diabetes, hepatitis C, osteoporosis, and allergies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056114

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel